vvus stock price  news  vivus inc  wall street journal dow jones a news corp company news corp is a network of leading companies in the worlds of diversified media news education and information services dow jones barrons bigcharts djx dow jones newswires factiva financial news mansion global marketwatch newsmart newsplus private markets risk  compliance wsjcom wsj pro wsj conference wsj video news corp big decisions business spectator checkout harper collins new york post proptiger rea realtorcom storyful the australian the sun the times djia ▲     sp  ▲     nasdaq ▲     us  yr ▲  yield    crude oil ▲     euro ▲     subscribe now sign in the wall street journal us edition us asia europe india  china  japan july   todays paper sections my journal home world us politics economy business tech markets opinion arts life real estate todays paper show all sections hide all sections world home africa asia canada china europe latin america middle east economy world video us home economy law new york politics real time economics washington wire journal report us video whats news podcast politics home washington wire politics video wsjnbc news poll economy home real time economics economic forecasting survey economy video business home management techwsjd aerospace  defense autos  transportation commercial real estate consumer products energy entrepreneurship financial services food  services health care hospitality law manufacturing media  marketing natural resources retail cfo journal cio journal cmo today logistics report risk  compliance heard on the street business video journal report business podcast tech home cio journal geoffrey fowler christopher mims joanna stern li yuan billion dollar startup club tech video tech podcast startup stock trader markets home bonds commercial real estate commodities  futures currencies deals financial services funds stocks your money heard on the street moneybeat wealth adviser ahead of the tape cfo journal journal report market data markets video markets podcast moneybeat podcast watching your wealth podcast opinion home james freeman william a galston daniel henninger holman w jenkins william mcgurn peggy noonan mary anastasia ogrady jason riley kimberley a strassel books film television theater art masterpiece series music dance opera exhibition cultural commentary editorials commentary letters to the editor the weekend interview potomac watch podcast foreign edition podcast opinion video notable  quotable best of the web newsletter morning editorial report newsletter arts home books film television theater art masterpiece series arts video wsj magazine life home careers cars food  drink health ideas real estate science sports style  fashion travel life video wsj magazine wsj puzzles the future of everything real estate home commercial real estate house of the day mansion real estate video hide all sections aim higher reach further get the wall street journal  for  weeks subscribe now sign in reveal navigation options subscribe sign in vivus inc vvus us nasdaq search view all companies at close  pm edt   usd   volume  after hours  pm edt     after hours vol  volume   day avg vol   day range     week range        d  d  m  m ytd  y  y   advanced charting compare compare to benchmark djia sp  global dow nasdaq health carelife sciences compare to add open  prior close    day vvus  djia  russell k  health carelife sciences  overview overview profile financials income statement balance sheet cash flow research  ratings historical prices options advanced charting news vivus incvvus significant news only  dow jones newswires vivus files k  entry into definitive agreement dow jones newswires  press release vivus announces settlement with actavis on qsymiar patent litigation press release  press release biotech stock performance review  vertex pharma vivus xbiotech and axovant sciences press release  dow jones newswires vivus files k  changes exec mgmt dow jones newswires  press release cncn thomas b king joins vivus board of directors press release  press release thomas b king joins vivus board of directors press release  press release how these biotech stocks are faring  seattle genetics sangamo therapeutics vertex pharma and vivus press release  press release vivus reports  first quarter financial results press release  press release cncn vivus reports  first quarter financial results press release  press release  vvus  investor network vivus inc to host earnings call press release  marketwatchcom some ‘cheap’ biotech stocks that could be buyout targets rbc says marketwatchcom  marketwatchcom valeant’s use of specialty pharmacy channel is typical of the industry marketwatchcom load more key stock data  pe ratio ttm the price to earnings pe ratio a key valuation measure is calculated by dividing the stocks most recent closing price by the sum of the diluted earnings per share from continuing operations for the trailing  month period earnings per share ttm a companys net income for the trailing twelve month period expressed as a dollar amount per fully diluted shares outstanding market capitalization reflects the total market value of a company market cap is calculated by multiplying the number of shares outstanding by the stocks price for companies with multiple common share classes market capitalization includes both classes shares outstanding number of shares that are currently held by investors including restricted shares owned by the companys officers and insiders as well as those held by the public public float the number of shares in the hands of public investors and available to trade to calculate start with total shares outstanding and subtract the number of restricted shares restricted stock typically is that issued to company insiders with limits on when it may be traded dividend yield a companys dividend expressed as a percentage of its current stock price key stock data pe ratio ttm   eps ttm  market cap  m shares outstanding  m public float  m yield vvus has not issued dividends in more than  year latest dividend na exdividend date na  shares sold short the total number of shares of a security that have been sold short and not yet repurchased change from last percentage change in short interest from the previous report to the most recent report exchanges report short interest twice a month percent of float total short positions relative to the number of shares available to trade short interest  shares sold short  m change from last  percent of float   money flow uptickdowntick ratio money flow measures the relative buying and selling pressure on a stock based on the value of trades made on an uptick in price and the value of trades made on a downtick in price the updown ratio is calculated by dividing the value of uptick trades by the value of downtick trades net money flow is the value of uptick trades minus the value of downtick trades our calculations are based on comprehensive delayed quotes stock money flow uptickdowntick trade ratio    net money flow   money flow gives a snapshot of relative buying and selling pressure in a stock a ratio above one suggests greater buying pressure below one suggests greater selling advertisement competitors vvus company change pe ttm cah cardinal health inc    lly eli lilly  co    pfe pfizer inc    abc amerisourcebergen corp    sny sanofi adr    rprx repros therapeutics inc    sphs sophiris bio inc    orex orexigen therapeutics inc    more information on vvus competitor data provided by capital cube profile vvus vivus inc operates as a biopharmaceutical company engages in the development and commercialization of novel therapeutic products it offers the qsymia for chronic weight management as well as stendra and spedra for erectile dysfunction its development also include  east evelyn avenue campbell california  united states email website map employees  sector pharmaceuticals sales or revenue  m industry health carelife sciences y sales change  fiscal year ends december  download reports seth h z fischer chief executive officer  director mark k oki chief financial  accounting officer santosh t varghese chief medical officer ted broman vice presidentchemistry manufacturing  control more research  ratings vivus incvvus pershare earnings actuals and estimates quarterly annual vvus will report fy  earnings on  vvus will report q earnings on  actual analyst range consensus      actual   actual   actual   actual     q q q q q q     actual     na fy  fy  fy  fy  q  estimate trends current   month ago   months ago  q  estimate trends current   month ago   months ago  fy  estimate trends current   month ago   months ago  fy  estimate trends current   month ago   months ago  more financials vivus incvvus quarterly annual net income  m m m  m mar  jun  sep  dec  mar   m  m m m m      mar  quarter trend net income growth  sales or revenue  m sales or revenue growth  ebitda  m  year trend net income growth  sales or revenue  m sales or revenue growth  ebitda  m more overview notes  data providers realtime us stock quotes reflect trades reported through nasdaq only international stock quotes are delayed as per exchange requirements indexes may be realtime or delayed refer to time stamps on index quote pages for information on delay times quote data except us stocks provided by six financial information data is provided as is for informational purposes only and is not intended for trading purposes six financial information a does not make any express or implied warranties of any kind regarding the data including without limitation any warranty of merchantability or fitness for a particular purpose or use and b shall not be liable for any errors incompleteness interruption or delay action taken in reliance on any data or for any damages resulting therefrom data may be intentionally delayed pursuant to supplier requirements all of the mutual fund and etf information contained in this display was supplied by lipper a thomson reuters company subject to the following copyright  thomson reuters all rights reserved any copying republication or redistribution of lipper content including by caching framing or similar means is expressly prohibited without the prior written consent of lipper lipper shall not be liable for any errors or delays in the content or for any actions taken in reliance thereon bond quotes are updated in realtime source tullett prebon currency quotes are updated in realtime source tullet prebon fundamental company data and analyst estimates provided by factset copyright factset research systems inc all rights reserved advertisement bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one vvus key statistics  vivus inc financial ratios  marketwatch bulletin investor alert expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close vivus inc nasdaq vvus go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus vivus inc after hours  quotes are delayed by  min jul    pm vvus quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite todays close     change   day low day high    week low  week high   company description vivus inc operates as a biopharmaceutical company engages in the development and commercialization of novel therapeutic products it offers the qsymia for chronic weight management as well as stendra and spedra for erectile dysfunction its development also include tacrolimus which is for the tre vivus inc operates as a biopharmaceutical company engages in the development and commercialization of novel therapeutic products it offers the qsymia for chronic weight management as well as stendra and spedra for erectile dysfunction its development also include tacrolimus which is for the treatment of pulmonary arterial hypertension the company was founded by virgil a place on april   and is headquartered in mountain view ca valuation pe current  pe ratio with extraordinary items  pe ratio without extraordinary items  price to sales ratio  price to book ratio  price to cash flow ratio  enterprise value to ebitda  enterprise value to sales  total debt to enterprise value  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability gross margin  operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure total debt to total equity  total debt to total capital  total debt to total assets  longterm debt to equity  longterm debt to total capital  officers and executives name age officer since title mr seth h z fischer   chief executive officer  director mr mark k oki   chief financial  accounting officer dr santosh t varghese   chief medical officer mr ted broman   vice presidentchemistry manufacturing  control dr sandra e wells   vice presidentpatents  assistant general counsel insider actions – purchase – sale  – number of transactions  date name shares transaction value  eric w roberts director      allan lee shaw director      eric w roberts director    derivativenonderivative trans at  per share   allan lee shaw director    derivativenonderivative trans at  per share   santosh t varghese chief medical officer    disposition at  per share   jorge plutzky director      eric w roberts director      eric w roberts director      david york norton director      herman rosenman director      allan lee shaw director      allan lee shaw director      eric w roberts director    derivativenonderivative trans at  per share   allan lee shaw director    derivativenonderivative trans at  per share   jorge plutzky director    derivativenonderivative trans at  per share   eric w roberts director    derivativenonderivative trans at  per share   david york norton director    derivativenonderivative trans at  per share   herman rosenman director    derivativenonderivative trans at  per share   allan lee shaw director    derivativenonderivative trans at  per share   eric w roberts director      allan lee shaw director      eric w roberts director    derivativenonderivative trans at  per share   allan lee shaw director    derivativenonderivative trans at  per share   santosh t varghese chief medical officer    disposition at  per share   eric w roberts director      allan lee shaw director      eric w roberts director    derivativenonderivative trans at  per share   allan lee shaw director    derivativenonderivative trans at  per share   north tide capital llc director    disposition at  per share   north tide capital llc director    disposition at  per share   north tide capital llc director    disposition at  per share   north tide capital llc director    disposition at  per share   north tide capital llc director    disposition at  per share  newslatestcompanyusvvus marketwatch news on vvus vivus inc stock rises  after regaining certain commercial rights for stendra from sanofi  am march    emma court vivus inc stock rises  after regaining stendras commercial rights in certain countries from sanofi  am march    emma court some ‘cheap’ biotech stocks that could be buyout targets rbc says  pm jan    emma court valeant’s use of specialty pharmacy channel is typical of the industry  am nov    francine mckenna vivus loss narrows as weightloss sales surge  pm may    marketwatchcom earnings deals aid medical supplier biopharmas on mixed market day  am oct    russ britt obesity drug makers jockey for position as analysts praise vivus  pm oct    russ britt what would grumpy cat short  am july    the trading deck hedge funds are buying these stocks right now  pm july    insider monkey boardroom peace means a drop in shares for embattled vivus  pm july    russ britt vivus claims allies in proxy war as does rogue investor  am july    russ britt vivus rogue shareholder trade salvos as boardroom war heats up  pm june    russ britt vivus shares drop as fight for control of company board heats up  pm june    russ britt  stocks insiders are buying  pm june    insider monkey study shows vivus qsymia may help sleep apnea  am nov    marketwatchcom vivus shares slide on weak dietdrug sales  pm nov    marketwatchcom friday’s biggest gaining and declining stocks  pm sept    greg morcroft vivus sees eu regulators rejecting diet drug  pm sept    marketwatchcom vivus falls  on eu drug approval update  pm sept    val brickates kennedy newsnonmarketwatchcompanyusvvus other news on vvus vivus settlement could clue in orexigen investors  pm july    seeking alpha quintiles ims a novel way to invest in biopharma  pm july    seeking alpha arena pharmaceuticals announces positive phase  results in pah  pm july    seeking alpha vivus settles with teva on weight management drug generic  am july    zackscom vivus settles lawsuit over qsymia generic  pm july    seeking alpha biomarin files bla for phenylketonuria candidate pegvaliase  am july    zackscom why is corcepts stock up more than  so far this year  am july    zackscom roche rhhby launches cobas test for bacterial infections  am july    zackscom amgens colorectal cancer drug gets fda nod to expand label  am june    zackscom roches rhhby leukemia drug gets prime status in eu  am june    zackscom acorda files nda for parkinsons disease candidate inbrija  am june    zackscom valeants vrx nda for bowel cleansing drug accepted by fda  am june    zackscom kempharm kmph strengthens its adhd prodrug pipeline  am june    zackscom neothetics fat reduction candidate fails in phase ii study  pm june    zackscom why is catalyst pharmaceuticals stock up  this year  am june    zackscom tevaxenon nerve pain candidate fails in phase ii study  am june    zackscom seattle genetics sgen reports positive data for adcetris  am june    zackscom bristolmyers reports data on immunooncology drug empliciti  am june    zackscom heres why investors are glued to vertex pharma vrtx stock  am june    zackscom regeneron regn stock on fire whats behind the surge  am june    zackscom loading more headlines at a glance vivus inc  east evelyn avenue suite  campbell california  phone   industry pharmaceuticals sector health carelife sciences fiscal yearend  view sec filings revenue m net income m  sales growth  employees  annual report for vvus newspressreleasecompanyusvvus press releases on vvus vivus announces settlement with actavis on qsymiar patent litigation  pm july    marketwired biotech stock performance review  vertex pharma vivus xbiotech and axovant sciences  am june    pr newswire  prf thomas b king joins vivus board of directors  pm may    marketwired how these biotech stocks are faring  seattle genetics sangamo therapeutics vertex pharma and vivus  am may    pr newswire  prf vivus reports  first quarter financial results  pm may    marketwired investor network vivus inc to host earnings call  am may    accesswire vivus announces date of  first quarter business update and financial results teleconference  am april    marketwired vivus inc reacquires stendrar avanafil commercial rights from sanofi  am march    marketwired research reports coverage on biotech stocks  vivus ultragenyx pharma cymabay therapeutics and omeros  am march    pr newswire  prf markets rally late to close in the green todays research reports on immunomedics and vivus  am march    accesswire vivus reports fourth quarter and full year  financial results  pm march    marketwired vivus announces date of  fourth quarter business update and financial results teleconference  am feb    marketwired biotechs rally shows no signs of slowing down todays reports on eyegate pharmaceuticals and vivus  am feb    accesswire research reports coverage on biotech stocks  emergent biosolutions chimerix vivus and rxi pharma  am jan    pr newswire  prf vivus and selten pharma announce agreement for the development and commercialization rights to treatments for pulmonary arterial hypertension pah  am jan    marketwired vivus reports  third quarter financial results  pm nov    marketwired pde inhibitors market   pm oct    pr newswire  prf vivus announces date of  third quarter business update and financial results teleconference  pm oct    marketwired vivus and metuchen pharmaceuticals announce license agreement for commercial rights to stendra  am oct    marketwired vivus extends return date of stendra commercial rights  pm aug    marketwired loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york closed marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pwall street isn’t ready for a point tumble in the dow industrials pbarrons buzz robo  facebook and twitter trading on news pa wild week in washington pthe dark side of cruises pthe highest paid athletes in the world in one chart poj simpson made over  while in prison and won’t have to give any of it to the goldman family p trump to police dont be too nice phere are  coworkers you should avoid like the plague — especially in meetings ptop  most annoying people you may want to unfriend on facebook pthis is one person you should never unfriend on facebook p horrible ways typos could alter the course of your life ppaint your bathroom this color and boost your home’s selling price by  pamericans’ new badge of honor ‘i was blocked by a celebrity’ p weird things i found out about america in my first  hours pbeyond tesla  stocks driving the autonomous car revolution pthese  highly taxed companies need congress to finally act on tax reform pwatch out ‘kids’ are making the most money in this stock market p real ways for millennials to save money not by brownbagging and skipping starbucks p‘game of thrones’ this computer model predicts who will be killed off — or survive pthis basic balanced index fund is beating the hedge fund averages loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft vivus  welcome homecorporate informationmanagement teamboard of directorscareerssearch open positionscontact usvivus oag supply chains act compliance statementproductsuseuclinical trialsmedical affairsrems programmedical education grantsmedical informationrequest medical informationinvestigatorinitiated trialsae  pc reportingnewsroompress releaseslogo downloadsinvestorspress releasesevents and presentationscorporate governancefinancial informationstock informationinvestors faqcontactemail usemail usmaps  directions rapidly advancing novel therapies vivus is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs more         frontpage slideshow  copyright   joomlaworks ltd vivus announces settlement with actavis on qsymiar patent litigation thomas b king joins vivus board of directors vivus reports  first quarter financial results vivus announces date of  first quarter business update and financial results teleconference vivus inc reacquires stendrar avanafil commercial rights from sanofi latest events there are currently no upcoming events a growing pipeline vivus is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs careers at vivus if you are passionate about making a difference in people’s lives vivus could be the place for you   vivus inc all rights reserved contactsitemapprivacy policyterms of usesite by formative vivus vvus will qsymia  stendra sales improve in   nasdaqcom hot topics etfs  smart portfolio  currencies  online broker center search vivus vvus will qsymia  stendra sales improve in  january    pm edt by zacks equity research zackscom shutterstock photo on jan  we issued an updated report on vivus inc vvus  vivus threemonth share price movement shows that the stock has significantly outperformed the zacks classified medicalbiomedgenetics industry specifically the company gained  during this period while the industry lost  the companys portfolio comprises two drugs  qsymia for chronic weight management and stendra eu trade name spedra for erectile dysfunction ed qsymia vivus key drug is the first weight loss product to be approved by the fda in  years however sales of the drug have been lackluster so far its uptake has been slow due to high outofpocket costs for patients owing to the lack of reimbursement for the product healthcare providers are often hesitant to treat obesity proactively despite the presence of evidence related to cardiometabolic benefits of weight loss among overweight and obese individuals qsymia faces intense competition too the branded obesity market has quite a few established players including arena pharmaceuticals incs arna belviq novo nordisks saxenda and orexigen therapeutics incs orex contrave vivus is working on ramping up qsymia sales through the expansion of reimbursement payments and promotional initiatives the company is also striving to improve patient access while reducing outofpocket costs for qsymia moreover the company is pursuing several programs to increase the utilization of the drug for the eligible patient population in jun  the company upgraded a qsymia patient savings offer in order to attract new patients and offer longterm support related to weight management another marketed product in the companys portfolio is stendra approved for the treatment of ed vivus has collaborations with several companies for the commercialization of stendra it has inked a licensing and commercialization deal with sanofi sny for the approval and commercialization of the drug in africa the middle east turkey and the commonwealth of independent states including russia moreover it has a deal with italybased privately held pharmaceutical company menarini in over  european countries australia and new zealand vivus inc price and consensus vivus inc price and consensus  vivus inc quote zacks rank vivus currently carries a zacks rank  hold you can see the complete list of todays zacks  rank stocks here  zacks top  stocks for  in addition to the stocks discussed above would you like to know about our  finest tickers for the entirety of  who wouldnt these  are painstakingly handpicked from  companies covered by the zacks rank they are our primary picks to buy and hold  be among the very first to see them  want the latest recommendations from zacks investment research today you can download  best stocks for the next  days click to get this free report sanofiaventis sny free stock analysis report vivus inc vvus free stock analysis report orexigen therap orex free stock analysis report arena pharma arna free stock analysis report to read this article on zackscom click here zacks investment research the views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of nasdaq inc this article appears in investing  business  stocks referenced symbols sny  vvus  orex  arna more from zackscom subscribe abbvie abbv tops q earnings  revenues outlook intact keryx kerx posts wider than expected loss in q sales beat alkermes alks q loss narrower than expected sales beat related stocks articles subscribe why bojangles inc stock dropped today   pm weatherford wft q loss in line revenues lag   pm yandex loses market share in spite of strong growth   pm contributorzackscom equity research follow on most popular highest rated mitel to acquire shoretel  quick facts sientra completes acquisition of miramar labs® seagate technology plc q profit rises  ledgerx gets us approval for derivatives on digital currencies us fines frontier american and delta for violating consumer shareholders approve major structural change to top performing yatra attains leadership position in corporate travel with the mitel to acquire shoretel  quick facts miller heiman group selects calliduscloud datahug for pipeline tractor supply company reports second quarter results view all highest rated research brokers before you trade compare online brokers want to trade fx visit our forex broker center  find a credit card select a credit card product by  card type  credit score  card issuer select an offer  apr credit cardsairline credit cardsbalance transfer credit cardsbusiness credit cardscash back credit cardscharge cardscharge cards for businessemv smart chipsgas cards  auto rewardshome improvement rewards credit cardsinstant approval credit cardslow interest credit cardsno annual fee credit cardsno foreign transaction fee credit cardspoints rewards credit cardsprepaid  debit cardsreward credit cardsstudent credit cardstop  best credit card deals and offers bad creditcredit quality averagecredit quality excellentcredit quality faircredit quality goodlimited or no credit historypersonal loans american expressamerican express airline cardsamerican express business cardsamerican express cash back credit cardsamerican express charge cardsbarclaycardcapital onecapital one cash backcapital one fair creditcapital one milescapital one pointscapital one prepaid credit cardschaseciti credit cardsdiscoverdiscover cashbackdiscover milesdiscover student credit cardsmastercard credit cardsus bankusaausaa savingsvisa credit cards search data provided by bankratecom stocks referenced sny  rate it vvus  rate it orex  rate it arna  rate it closex edit favorites enter up to  symbols separated by commas or spaces in the text box below these symbols will be available during your session for use on applicable pages update clear list closex customize your nasdaqcom experience background color selector select the background color of your choice  black  slate gray  light gray  gray blue quote search select a default target page for your quote search  realtime  after hours  premarket  news  flash quote  summary quote  interactive charts  default setting please note that once you make your selection it will apply to all future visits to nasdaqcom if at any time you are interested in reverting to our default settings please select default setting above if you have any questions or encounter any issues in changing your default settings please email isfeedbacknasdaqcom closex please confirm your selection you have selected to change your default setting for the quote search this will now be your default target page unless you change your configuration again or you delete your cookies are you sure you want to change your settings yes no closex please disable your ad blocker or update your settings to ensure that javascript and cookies are enabled so that we can continue to provide you with the firstrate market news and data youve come to expect from us closex products homecorporate informationmanagement teamboard of directorscareerssearch open positionscontact usvivus oag supply chains act compliance statementproductsuseuclinical trialsmedical affairsrems programmedical education grantsmedical informationrequest medical informationinvestigatorinitiated trialsae  pc reportingnewsroompress releaseslogo downloadsinvestorspress releasesevents and presentationscorporate governancefinancial informationstock informationinvestors faqcontactemail usemail usmaps  directions you are here home  products products now available for more information click here click below for full prescribing information qsymia™ full prescribing information qsymia™ medication guide for information about vivus products approved in the eu click here in this section useu   vivus inc all rights reserved contactsitemapprivacy policyterms of usesite by formative eu homecorporate informationmanagement teamboard of directorscareerssearch open positionscontact usvivus oag supply chains act compliance statementproductsuseuclinical trialsmedical affairsrems programmedical education grantsmedical informationrequest medical informationinvestigatorinitiated trialsae  pc reportingnewsroompress releaseslogo downloadsinvestorspress releasesevents and presentationscorporate governancefinancial informationstock informationinvestors faqcontactemail usemail usmaps  directions you are here home  products  eu products approved eu click below for full prescribing information spedra™ summary of product characteristics smpc the european commission ec granted the marketing authorization for spedra™ avanafil for the treatment of erectile dysfunction ed in the european union eu the approval of the marketing authorization application maa by the ec follows the positive recommendation by the european medicines agencys ema committee for medicinal products for human use chmp in april  spedra a pde inhibitor is the first new chemical entity nce approved for ed in over a decade a medical information healthcare professional is available to answer questions from healthcare professionals during business hours monday – friday from  –  local time at   amsterdam   united kingdom if you are a patient please discuss any questions you may have with your healthcare provider after hours you may leave a message after hours from  –  local time monday – friday and all day sunday saturday and holiday for information about vivus products approved in the us click here in this section useu   vivus inc all rights reserved contactsitemapprivacy policyterms of usesite by formative vivus inc  mountain view  santa clara county  castro street company directory and business data solutions about kompass register login login × please fill in your login and password register login forgot your password  english contact kompass north america please contact one of our team of experts from monday to friday between am and pm or by email     contact us search across  million selected companies in more than  countries or all suppliers one company rechercher data access business solutions sales leads online promotion easybusiness easylist free guide  bb prospecting success kompasspublictenders credit card payment webinar digital solutions booster promotional solutions register your company see all business solutions videos  tutorials quizz easybusiness find the right sales leads with more than  million companies and  search criteria our global bb database easybusiness will help you find the right customer leads and marketing lists find out more  easylist need help with finding prospects easylist is our straightforward on demand tool designed to help you build personalised company lists from a global database of  million companies find out more register your company build your free company profile if you are looking to expand into new markets or want to grow your sales activity then register your company free of charge on the global kompass bb directory find out more  booster engage your target audience engage your target audience and attract new business leads using the kompasscom our global online digital directory with over m visitors per month from  countries worldwide let us improve your seo and increase your customer traffic find out more  promotional solutions attract relevant enquiries build enhance and manage your company profile to attract visitors instantly use our ppc experts to help drive relevant enquiries through to your profile – cost effective managed and guaranteed find out more  free guide bb prospecting success best strategy to find targeted leads and drive great sales results publictenders publictenders public tenders payment portal payment portal credit card payment portal webinar skyrocketing your government contracting public tenders webinar learn about the value of selling to the us government key market challenges and how to find and respond to opportunities throughout the usa  plus get three months free access to the database california santa clara county vivus inc x every month we have millions of visitors on kompass looking for companies like yours register your company on kompass and build your free company profile to attract those visitors register login login vivus inc  castro street mountain view ca  united states need to contact this company call click to see their phone number call click to see their phone number  service   call price  this phone number available for  min is not the recipients number but a number from a service which will put you through to that person this service is produced by kompass  why this number  service  free calls  this number only available  minutes is not your correspondants number but the number of a service putting you through to that person this service is produced by kompass  why this number  all the lines are busy at the moment please try again in a moment view map location view their website purchase online company lists of companies create your prospect list  vivus inc × addresses of  vivus inc × description key figures executives activities description key figures executives activities company summary vivus inc is a specialty pharmaceutical company that focuses on the research development and commercialization of products to restore sexual function in women and men the companys product pipeline includes four clinical stage product candidates evamista a product candidate to alleviate symptoms associated with menopause avanafil a phosphodiesterase type five pde inhibitor product candidate for the treatment of erectile dysfunction alista a product candidate for the treatment of female sexual arousal disorder fsad and testosterone mdts a product candidate to treat hypoactive sexual desire disorder hsdd vivus markets muse as a prescription product for the treatment of erectile dysfunction vivus inc develops treatments for erectile dysfunction ed and other sexual disorders their product is a small disposable plastic applicator that dispenses a localized dose of the drug alprostadil as a treatment for ed the company focuses on treating sexual dysfunction in both men and women and also obesity and diabetes general information year established  type of company head office fax    fps website httpwwwvivuscom key figures employees company  employees turnover  over  million usd executives executive information download the executives list mario rosati secretary l f w president president chief executive officer and director v a p chairman of the board and chief scientific officer l j s chief financial officer vice presidentfinance n g vice president clinical research g p m vice president of us operations j r n vice presidentclinical medicine t m n vice president corporate development and international marketing p y t vice president strategic planning and corporate development president c z vice president regulatory affairs l d md m m senior vice president chief commercial officer t n vice president business development and international market c w business development m a chairman s f ceo j e vice president  business development general counsel w d vice president  clinical development l w information technology director s k director of managed care and contracting j p independent director r t director quality j l independent director j p director consumer marketing activities activities producer distributor service provider honey products propolis barbiturates sulphonamides glycosides alkaloids and antibiotics carbohydrates proteins and enzymes coenzyme q pharmaceutical preparations for the central and autonomic nervous system and anaesthetics anaesthetics basal anaesthetics inhalation anaesthetics intravenous iv anaesthetics spinal anaesthetics local anaesthetic ether anaesthetic chloroform analeptics analgesics antialzheimer agents anticholinergics anticonvulsants antiepileptics antiinflammatory preparationsantiphlogistics antiinflammatories nonsteroidal antineuralgics antiparkinson agents antipyretics antiarthritics antirheumatic preparations hematoporphyrin and preparations stimulants and antidepressive agents for the central nervous system hypnotics opiates sedatives and tranquillisers psychotropic products muscle relaxants and their antagonists phenylisopropylamine and salts amphetamine sympatholytics parasympathomimetics sympathomimetics calcium antagonists neurological preparations pharmaceutical preparations for the cardiovascular system blood coagulants and haemostatics anticoagulants for blood antithrombins blood decompressants haemopoietics cardioaccelerators cardioregulators pharmaceutical cardiovascular products cardiotonics antiarrhythmic preparations angiotonics coronary vasodilators peripheral vasodilators antivaricose preparations hypertensive agents hypotensive agents pharmaceutical preparations for ear nose and throat ent and dentistry aural preparations oropharyngeal preparations nasopharyngeal preparations nasal creams nasal sprays throat sprays mouthwashes and throat washes pharmaceutical dental preparations pharmaceutical preparations for ophthalmology eye ointments eyedrops collyriums pharmaceutical ophthalmic preparations mydriatic eyewashes pharmaceutical steroid preparations for ophthalmic use ophthalmic preparations nes pharmaceutical preparations for metabolism nutrition alimentary systems antidismetabolics antiobesity preparations anorectics antianaemics bile and bile salt preparations cholesterol reducing agents appetite stimulants foods and nutrients herbal extracts dietary eutrophics pharmaceutical preparations for metabolism nes antidiabetic pharmaceuticals anabolic agents ferritin iron preparations medical pharmaceutical preparations for dermatology dermatological fungicides and keratolytics dermatological ointments and shampoos dermatological sedatives local keratolytics dermatological stimulants antipruritics calamine lotion creams nappy rash prevention antiacne preparations steroid preparations for dermatological use antipsoriatics antiburn preparations creams chilblain prevention lip balm lipsalve medicated wart removing preparations corn removing preparations pharmaceutical preparations for urology gynaecology and obstetrics contraceptive agents chemical galactagogues galactophores milk secretion stimulants pharmaceutical emmenagogues vaginal preparations nes pharmaceuticals gynaecological and obstetrical nes diuretics antidiuretics antienuretics antiurics uricosuric agents pharmaceuticals for urinary tract disorders nes pharmaceuticals for renal disorders antiprostatics erectile dysfunction drugs pharmaceutical preparations for pneumology catarrh preparations cough syrups respiratory stimulants asthma preparations cigarettes medical for asthmatics bronchodilators chemotherapeutic preparations gastroenterology and hepatology preparations antacids and preparations for gastric ulcers antidiarrhoeal preparations carminatives cholagogues choleretics hepatoprotectors hepatic products laxatives and purgatives laxatives fig based digestives eupeptics stomachics emetics antiemetics and antinauseants enema fluids antilithiasis products omeprazole pharmaceuticals for gastrointestinal disorders nes immunological preparations antiseptics and antibacterial preparations skin and wound disinfectants surgical spirit pharmaceutical preparations nes biopharmaceuticals pharmaceutical preparations vegetable based pharmaceutical preparations generic radiopharmaceutical products electrode creams and gels diaphoretics antiallergic preparations and antihistamines anhidrotics allergens for diagnostic and desensitisation purposes diagnostic kits medical biochemical diagnostic aids and tests nes surgical glue haemostatic sponges collagen oils and liquid paraffin for pharmaceuticals fish oils and fish oil extracts for medical use colourants edible for pharmaceuticals flavourings for pharmaceuticals emulsifying agents for pharmaceuticals solvents for pharmaceuticals balsams natural and synthetic for pharmaceuticals petrolatumpetroleum jelly vaseline for pharmaceuticals pharmaceutical excipients electrolytes intravenous iv application plasma substitutes dialysis fluids ointment bases for pharmaceuticals coal tar bases antiseptic and disinfectant glucose solution pharmaceutical infusion solutions subcutaneous and intravenous iv solutions for haemodialysis capsules gelatine for pharmaceuticals capsules soft vegetable starch based for pharmaceuticals collodions for pharmaceutical use sequestering agents for pharmaceuticals microcrystalline cellulose for pharmaceuticals cinchophen guaiaphenesin chondroitin sulphate capsules methylcellulose for pharmaceuticals plasters medical liquid medicinal pastilles and lozenges emulsions pharmaceutical oils medicated powders medicated tablets effervescent pharmaceutical to customer specification parapharmaceutical preparations cough preparations parapharmaceutical inhalants parapharmaceutical blood tonics parapharmaceutical nerve tonics parapharmaceutical melissa cordials tonic preparations for sportsmen depuratives parapharmaceutical cod liver oil and halibut oil preparations salt tablets medicinal nicotine replacement therapy products antitravel sickness tablets haemorrhoidal preparations slimming preparations parapharmaceutical cicatrizants liniments embrocations emollients parapharmaceutical medicated pencils or sticks insect repellents parapharmaceutical insectbite lotions jellyfish repellents parapharmaceutical tinctures pharmaceutical poultices mud bath preparations earplugs wax solvents adhesive plaster removing solutions contact lens cleaning shark cartilage products parapharmaceutical dietary supplements mineral or vitamin based parapharmaceutical products dead sea minerals based aromatherapy preparations herb or grain filled cushions herbal preparations medicinal herbs and infusions homeopathic preparations emu oil products parapharmaceutical ultrasonic equipment for biological and medical applications medical and surgical instruments ultrasonic medical equipment and instruments medical instruments electric medical instruments electronic needles serum needles fistula syringe pumps electronic dosing syringes automatic injection syringes manual syringe accessories medical needles acupuncture needles and accessories hypodermic needles electrolysis needles platinum for electrocautery skeleton preparation equipment surgical equipment and instruments surgical instruments electric surgical instruments electronic surgical instruments hard metal surgical instruments soft metal scalpels surgical lancets surgical disposable knives surgical trocars surgical saws surgical bone drills surgical bone rongeurs surgical clamps surgical retractors surgical forceps surgical bone forceps surgical clips surgical mouth gags props wedges and jacks surgical dilators surgical staplers surgical needles suture high frequency surgery systems and equipment surgical systems intelligent prostatectomy instruments lithotrity and lithotomy instruments instruments for heart surgery angioplasty balloons and catheters neurosurgery instruments autopsy instruments surgical equipment and instruments needles ophthalmic surgery instruments cataract surgery instruments iridectomy instruments strabismic surgery instruments eyelid surgery instruments tear duct surgery instruments ophthalmic enucleation tonsillotomes eardrum perforatorsmyringotomy blades bone nailing apparatus surgical instruments shoulder surgery osteoclasts periosteotomes instruments for bone and tendon grafting skin graft blades skull trepanning tools instruments for mastoidectomy razors surgical curettes surgical splinter removal pencils magnetic surgical clips metal surgical tubing skin marking instruments surgical sealant applicators for surgical wounds abdominal wound closure aids silicone handles stainless steel and nickel silver for surgical instruments blood transfusion equipment needles blood transfusion medical examination equipment lancets for blood collection bone setting osteosynthesis tools stethoscopes stethoscopes electronic tongue depressors medical orthopaedic equipment surgical instruments orthopaedic for arthrodesis osteotomes bone guide wires orthopaedic impactors orthopaedic urology equipment urethrotomes instruments and catheters for urology and urodynamics gynaecological and obstetrical equipment test kits pregnancy cervix vibratordilators vaginal specula colposcopes medical equipment ear nose and throat ent rhinomanometers otoscopes nasal specula nose bridge straighteners ear baths equipment for the nervous system reflex hammers diagnostic equipment for the cardio vascular system phonocardiographs pulse meters medical gastroenterology and hepatology equipment gastroscopes metabolism and nutrition equipment insulin pens and accessories dermatology equipment dermatological instruments dermographic pencils textile articles for medical and surgical use research general you might also like contact vivus inc call click to see their phone number call click to see their phone number  service   call price  this phone number available for  min is not the recipients number but a number from a service which will put you through to that person this service is produced by kompass  why this number  service  free calls  this number only available  minutes is not your correspondants number but the number of a service putting you through to that person this service is produced by kompass  why this number  all the lines are busy at the moment please try again in a moment you might also like pharmacyclics inc   sunnyvale pharmaceutical preparations for the central and autonomic nervous system and anaesthetics telik inc   palo alto pharmaceutical preparations for the central and autonomic nervous system and anaesthetics hillestad pharmaceuticals   woodruff pharmaceutical preparations for the central and autonomic nervous system and anaesthetics alexza pharmaceuticals in   mountain view pharmaceutical preparations for the central and autonomic nervous system and anaesthetics cytomedix inc   gaithersburg pharmaceutical preparations for the central and autonomic nervous system and anaesthetics neorx corp washington   san francisco pharmaceutical preparations for the central and autonomic nervous system and anaesthetics perlegen sciences   mountain view pharmaceutical preparations for the central and autonomic nervous system and anaesthetics pharmasset inc   princeton pharmaceutical preparations for the central and autonomic nervous system and anaesthetics somaxon pharmaceuticals i   san diego pharmaceutical preparations for the central and autonomic nervous system and anaesthetics viropharma inc   exton pharmaceutical preparations for the central and autonomic nervous system and anaesthetics xenoport inc   santa clara pharmaceutical preparations for the central and autonomic nervous system and anaesthetics micro laboratories   mentor pharmaceutical preparations for the central and autonomic nervous system and anaesthetics cv therapeutics inc   palo alto pharmaceutical preparations for the central and autonomic nervous system and anaesthetics micromet inc   carlsbad pharmaceutical preparations for the central and autonomic nervous system and anaesthetics nitromed inc   lexington pharmaceutical preparations for the central and autonomic nervous system and anaesthetics nutra pharma corp   coral springs pharmaceutical preparations for the central and autonomic nervous system and anaesthetics nutracea   el dorado hills pharmaceutical preparations for the central and autonomic nervous system and anaesthetics cpc scientific inc   san jose pharmaceutical preparations for the central and autonomic nervous system and anaesthetics atley pharmaceuticals inc   ashland pharmaceutical preparations for the central and autonomic nervous system and anaesthetics wellness international ne   plano pharmaceutical preparations for the central and autonomic nervous system and anaesthetics our business solutions with kompass  global presence in more than  countries detailed and up to date company information comprehensive and filtered company directory frequent updates ensuring high quality data secure online payment help with expert advice dedicated customer service team contact kompass north america contact us vivus inc  fda advisory committee recommends approval of qnexa® print page   email page   download pdf    « previous release  next release » fda advisory committee recommends approval of qnexa® mountain view calif feb   prnewswire  vivus inc nasdaq vvus today announced that the us food and drug administration endocrinologic and metabolic drugs advisory committee recommended qnexa be granted marketing approval by the fda for the treatment of obesity in adults the committee voted  to  on the recommendation for an approval based on a favorable benefitrisk profile we are pleased with the panels approval recommendation in support of the safety and efficacy of qnexa said peter tam president of vivus we look forward to working with the fda as they complete their evaluation obesity is a serious medical condition and we are committed to making qnexa available and providing physicians with a new medical treatment option in their battle with this public health epidemic the fda is not bound by the recommendations of its advisory committees but will consider the guidance during the review of the new drug application nda that was submitted for qnexa in october  the scheduled prescription drug user fee act pdufa date for qnexa is april   note to investors vivus will hold a conference call to discuss this update today february   beginning at  pm eastern time you can listen to this call by dialing toll free  or  a day archive of the call can be accessed at httpirvivuscom about qnexa controlled release capsules qnexa kyooneksuh is an investigational drug candidate being developed to address weight loss type  diabetes and obstructive sleep apnea qnexa is a onceaday proprietary oral controlledrelease formulation of lowdose phentermine and topiramate which is designed to decrease appetite and increase satiety the sense of feeling full the two main mechanisms that impact eating behavior in phase  and  clinical data to date patients taking qnexa have demonstrated statistically significant weight loss glycemic control and improvement in cardiovascular risk factors when used in combination with a diet and lifestyle modification program about vivus vivus is a biopharmaceutical company developing therapies to address obesity sleep apnea diabetes and male sexual health  the companys lead investigational product in clinical development qnexa has completed phase  clinical trials for the treatment of obesity and is currently being considered for approval by us and eu regulators  vivus received a complete response letter or crl to the initial qnexa nda on october    we resubmitted the qnexa nda in october  with an fda action date of april    qnexa is also in phase  clinical development for the treatment of type  diabetes and obstructive sleep apnea  in the area of sexual health vivus has submitted an nda for avanafil a pde inhibitor being studied for the treatment of erectile dysfunction with an fda action date of april    for more information about the company please visit wwwvivuscom  certain statements in this press release are forwardlooking within the meaning of the private securities litigation reform act of   these statements may be identified by the use of forwardlooking words such as anticipate believe forecast estimate expect intend likely may plan potential predict opportunity and should among others  there are a number of factors that could cause actual events to differ materially from those indicated by such forwardlooking statements  these factors include but are not limited to the response from the united states food and drug administration or fda to our resubmission of the new drug application or nda for qnexa for the treatment of obesity including weight loss and maintenance of weight loss recommended for obese patients bmi ≥ kgm or overweight patients bmi ≥ kgm with weightrelated comorbidities such as hypertension type  diabetes dyslipidemia or central adiposity abdominal obesity with a contraindication that excludes the use of qnexa by women who are pregnant the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy or the fortress study the reliability of the electronic medical claims healthcare databases used in the fortress study the fdas interpretation of and agreement with the information vivus submitted relating to teratogenicity and cardiovascular safety the fdas interpretation of the data from our sequel study ob and sleep apnea study ob that we may be required to provide further analysis of clinical trial data our response to questions and requests for additional information including additional preclinical or clinical studies from the european medicines agency or ema and the committee for medicinal products for human use or chmp of the marketing authorization application or maa for qnexa the results of external studies to assess the teratogenic risk of topiramate results of the rems or cardiovascular outcomes for obesity advisory meetings the voting results of the second advisory committee meeting for qnexa the impact if any of the agreement by one of our competitors with an obesity compound to conduct or complete a cardiovascular outcomes study preapproval impact on future sales based on specific indication and contraindications contained in the label and extent of the rems distribution and patient access program the fdas response to the nda filed for avanafil our ability to successfully commercialize or establish a marketing partnership for avanafil or our partners ability to obtain regulatory approval to manufacture and adequately supply avanafil for commercial use our history of losses and variable quarterly results substantial competition risks related to the failure to protect our intellectual property and litigation in which we may become involved uncertainties of government or third party payer reimbursement our reliance on sole source suppliers our limited sales and marketing efforts and our reliance on third parties failure to continue to develop innovative investigational drug candidates and drugs risks related to the failure to obtain fda or foreign authority clearances or approvals and noncompliance with applicable regulations our ability to demonstrate through clinical testing the safety and effectiveness of our investigational drug candidates our dependence on the performance of our collaborative partners the timing of initiation and completion of clinical trials and submissions to the fda or foreign authorities the volatility and liquidity of the financial markets our liquidity and capital resources and our expected future revenues operations and expenditures  as with any pharmaceutical in development there are significant risks in the development the regulatory approval and commercialization of new products there are no guarantees that our response to the fdas crl or chmps day list of outstanding issues the fdas requests stemming from the endofreview meeting or the results of the fortress study and subsequent meetings and communications will be sufficient to satisfy the fda or chmps safety concerns that the fda or foreign authorities will not require us to conduct any additional prospective studies or retrospective observational studies or that any product will receive regulatory approval for any indication or prove to be commercially successful  vivus does not undertake an obligation to update or revise any forwardlooking statements  investors should read the risk factors set forth in vivus form k for the year ending december   and periodic reports filed with the securities and exchange commission contact   vivus inc   media relations golinharris timothy e morris   susan brophy chief financial officer   sbrophygolinharriscom         investor relations the trout group   brian korb   bkorbtroutgroupcom    source vivus inc news provided by acquire media close window  back to top vivus  welcome homecorporate informationmanagement teamboard of directorscareerssearch open positionscontact usvivus oag supply chains act compliance statementproductsuseuclinical trialsmedical affairsrems programmedical education grantsmedical informationrequest medical informationinvestigatorinitiated trialsae  pc reportingnewsroompress releaseslogo downloadsinvestorspress releasesevents and presentationscorporate governancefinancial informationstock informationinvestors faqcontactemail usemail usmaps  directions rapidly advancing novel therapies vivus is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs more         frontpage slideshow  copyright   joomlaworks ltd vivus announces settlement with actavis on qsymiar patent litigation thomas b king joins vivus board of directors vivus reports  first quarter financial results vivus announces date of  first quarter business update and financial results teleconference vivus inc reacquires stendrar avanafil commercial rights from sanofi latest events there are currently no upcoming events a growing pipeline vivus is a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious unmet medical needs careers at vivus if you are passionate about making a difference in people’s lives vivus could be the place for you   vivus inc all rights reserved contactsitemapprivacy policyterms of usesite by formative vivus inc vvuso company profile  reuterscom x edition united states africa américa latina عربي argentina brasil canada  deutschland españa france india italia  méxico россия united kingdom united states profile vivus inc vvuso related topics stocksstock screenerhealthcarepharmaceuticals overview news key developments people charts financials analysts research pulse vvuso on nasdaq usd  jul  change  chg   prev close  open  days high  days low  volume  avg vol  wk high  wk low  full description vivus inc incorporated on may   is a biopharmaceutical company the company operates in the development and commercialization of therapeutic products segment it provides over two therapies approved by the united states food and drug association fda which include qsymia phentermine and topiramate extended release for chronic weight management and stendra avanafil for erectile dysfunction ed the company is also developing qsymia for the treatment of obstructive sleep apnea osa and diabetes stendra is also approved by the european commission ec under the name spedra for the treatment of ed in the europeqsymiathe companys qsymia is indicated for chronic weight management as an adjunct to a reducedcalorie diet and physical activity in adult patients with an initial body mass index bmi of  or greater or obese patients or a bmi of  or greater or overweight patients in the presence of approximately one weightrelated comorbidity such as hypertension type ii diabetes mellitus or high cholesterol dyslipidemia the companys product incorporates a formulation combining doses of active ingredients from phentermine and topiramate qsymia is available in over  certified retail pharmacies across the country the company commercializes qsymia in the united states through contract sales force supported by an internal commercial team consisting of sales management marketing and managed care professionals the company has completed the phase ii studies of qsymia for the indication of osa and diabetes the company also has rights for commercialization of qsymia for osa obesity and diabetes across the worldstendrathe companys stendra is an oral phosphodiesterase type  pde inhibitor the united states food and drug association approved a supplemental new drug application snda for stendra stendra is an ed medication indicated to be taken approximately  minutes before sexual activity the company has granted license to menarini group to commercialize and promote spedra for the treatment of ed in over  european countries including the europe australia and new zealand in addition it has granted license to endo international plc to market stendra in the united states and canada the company competes with arena pharmaceutical orexigen therapeutics roche glaxosmithkline akrimax pharmaceuticals llc novo nordisk as johnson  johnsons janssen pharmaceuticals astrazeneca bristolmyers squibb boehringer ingelheim and eli lilly » full overview of vvuso company address vivus inc  e evelyn avemountain view   ca    p f  company web links home page officers  directors name compensation david norton  seth fischer  mark oki  john slebir  guy marsh  » more officers  directors vivus inc news vivus teva settle lawsuit over tevas planned generic qsymia jul   briefvivus announces settlement with actavis on qsymia patent litigation jul   briefvivus reports q loss per share  may   briefvivus reacquires stendraravanafilcommercial rights from sanofi mar   » more vvuso news related topics stocksstock screenerhealthcarepharmaceuticals vivus inc  vvus  stock price today  zacks free gift for zackscom visitors vvus is up  today but wheres it headed in august privacy policy no cost no obligation to buy anything ever join sign in member sign in keep me signed in what does remember me do forgot password create a new account you are being directed to zackstrade a division of lbmz securities and licensed brokerdealer zackstrade and zackscom are separate companies the web link between the two companies is not a solicitation or offer to invest in a particular security or type of security zackstrade does not endorse or adopt any particular investment strategy any analyst opinionratingreport or any approach to evaluating indiv idual securities if you wish to go to zackstrade click ok if you do not click cancel ok cancel back to top more vivus inc vvus delayed data from nsdq  usd     updated jul    pm et add to portfolio zacks rank hold          style scores a value  d growth  b momentum  b vgm the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores industry rank top  out of  industry medical  biomedical and genetics view all zacks  ranked stocks trades from  this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn about the zacks rank zacks rank home  zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank quote overview stock activity open  day low  day high   wk low   wk high  avg volume  market cap  m dividend    beta  key earnings data earnings esp  most accurate est  current qtr est  current yr est  exp earnings date  prior year eps  exp eps growth yrna forward pe na peg ratio na medical » medical  biomedical and genetics zacks earnings esp expected surprise prediction looks to find companies that have recently seen positive earnings estimate revision activity the idea is that more recent information is generally speaking more accurate and can be a better predictor of the future which can give investors an advantage in earnings season the technique has proven to be very useful for finding positive surprises in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time while they also saw  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings research reports for vvus     all zacks’ analyst reports news for vvus zacks news for vvus other news for vvus vivus settles with teva on weight management drug generic am est zacks biomarin files bla for phenylketonuria candidate pegvaliase am est zacks vvus what are zacks experts saying now zacks private portfolio services why is corcepts stock up more than  so far this year am est zacks roche rhhby launches cobas test for bacterial infections am est zacks amgens colorectal cancer drug gets fda nod to expand label am est zacks more zacks news for vvus vivus settlement could clue in orexigen investors am est seeking alpha quintiles ims a novel way to invest in biopharma am est seeking alpha arena pharmaceuticals announces positive phase  results in pah am est seeking alpha vivus announces settlement with actavis on qsymiar patent litigation pm est marketwire vivus settles lawsuit over qsymia generic am est seeking alpha more other news for vvus premium research for vvus zacks rank hold  zacks industry rank top  out of  zacks sector rank bottom   out of  style scores a value  d growth  b momentum  b vgm earnings esp  research reports for vvus analyst  snapshot this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to get access to the zacks rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports zacks earnings esp expected surprise prediction looks to find companies that have recently seen positive earnings estimate revision activity the idea is that more recent information is generally speaking more accurate and can be a better predictor of the future which can give investors an advantage in earnings season the technique has proven to be very useful for finding positive surprises in fact when combining a zacks rank  or better and a positive earnings esp stocks produced a positive surprise  of the time while they also saw  annual returns on average according to our  year backtest visit the earnings esp center see the full list of stocks to beat earnings this is our short term rating system that serves as a timeliness indicator for stocks over the next  to  months how good is it see rankings and related performance below zacks rank definition annualized return  strong buy   buy   hold   sell   strong sell  sp   zacks rank education  learn more about the zacks rank zacks rank home  all zacks rank resources in one place zacks premium  the only way to fully access the zacks rank the zacks industry rank assigns a rating to each of the  x expanded industries based on their average zacks rank an industry with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s the industry with the best average zacks rank would be considered the top industry  out of  which would place it in the top  of zacks ranked industries the industry with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks industry rank education  learn more about the zacks industry rank the zacks sector rank assigns a rating to each of the  sectors based on their average zacks rank a sector with a larger percentage of zacks rank s and s will have a better average zacks rank than one with a larger percentage of zacks rank s and s zacks sector rank education  learn more about the zacks sector rank the sector with the best average zacks rank would be considered the top sector  out of  which would place it in the top  of zacks ranked sectors the sector with the worst average zacks rank  out of  would place in the bottom  zacks rank education  learn more about the zacks rank zacks sector rank education  learn more about the zacks sector rank the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the three scores are based on the trading styles of growth value and momentum growth score a value score a momentum score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b zacks style scores education  learn more about the zacks style scores the style scores are a complementary set of indicators to use alongside the zacks rank it allows the user to better focus on the stocks that are the best fit for his or her personal trading style the scores are based on the trading styles of value growth and momentum theres also a vgm score v for value g for growth and m for momentum which combines the weighted average of the individual style scores into one score value score a growth score a momentum score a vgm score a within each score stocks are graded into five groups a b c d and f as you might remember from your school days an a is better than a b a b is better than a c a c is better than a d and a d is better than an f as an investor you want to buy stocks with the highest probability of success that means you want to buy stocks with a zacks rank  or  strong buy or buy which also has a score of an a or a b in your personal trading style zacks style scores education  learn more about the zacks style scores the zacks equity research reports or zer for short are our inhouse independently produced research reports the ever popular onepage snapshot reports are generated for virtually every single zacks ranked stock its packed with all of the companys key stats and salient decision making information including the zacks rank zacks industry rank style scores the price consensus  surprise chart graphical estimate analysis and how a stocks stacks up to its peers the detailed multipage analyst report does an even deeper dive on the companys vital statistics in addition to all of the proprietary analysis in the snapshot the report also visually displays the four components of the zacks rank agreement magnitude upside and surprise provides a comprehensive overview of the company business drivers complete with earnings and sales charts a recap of their last earnings report and a bulleted list of reasons to buy or sell the stock it also includes an industry comparison table to see how your stock compares to its expanded industry and the sp  researching stocks has never been so easy or insightful as with the zer analyst and snapshot reports learn more about zacks equity research reports see more zacks equity research reports   change in last  days view all zacks rank  strong buys premium research industry analysis top peers symbol zacks rank vivus inc vvus bioverativ inc bivv cellectis sa clls enzo biochem inc enz exelixis inc exel vertex pharmaceuticals incorporated vrtx aveo pharmaceuticals inc aveo see all medical  biomedical and genetics peers price and eps surprise chart  month  months ytd interactive chart  fundamental chart billion dollar secret company summary vivus is a biopharmaceutical company developing innovative nextgeneration therapies to address unmet needs in obesity diabetes and sexual health the companys lead investigational product in clinical development qnexatm is expected to complete phase  clinical trials for the treatment of obesity in  qnexa is also in phase  clinical development for the treatment of type  diabetes in the area of sexual health vivus is in phase  development with avanafil its pde inhibitor drug candidate and in phase  development of luramisttm its drug candidate for the treatment of hypoactive sexual desire disorder hsdd in women muser alprostadil a first generation therapy for the treatment of ed is already on the market and generating revenue for vivus